Mirtazapin Abz (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Abz, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral dosage form for oral use. It is prescribed for the treatment of major depressive disorder in adult patients. GNH USA supplies Mirtazapin Abz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine acts within the central nervous system to alleviate depressive symptoms and is indicated for the following condition: - Major depressive disorder: improves mood, sleep, appetite and overall functional capacity in adults.

Mirtazapine may cause a range of adverse reactions.

Common Side Effects: - Sedation or drowsiness: feeling unusually sleepy, especially at treatment onset. - Increased appetite and weight gain: heightened hunger leading to gradual weight increase. - Dry mouth: reduced salivation causing oral discomfort. - Constipation: slower intestinal motility. - Dizziness: light‑headed sensation, particularly when standing quickly. - Fatigue: general lack of energy.

Serious or Rare Side Effects: - Agranulocytosis or neutropenia: markedly reduced white blood cells, increasing infection risk. - Severe hypersensitivity reactions: rash, swelling, or difficulty breathing. - Serotonin syndrome: agitation, hyperthermia, muscle rigidity when combined with other serotonergic agents. - Suicidal thoughts or behavior: emergence of new or worsening suicidal ideation. - Hepatotoxicity: abnormal liver function tests. - Orthostatic hypotension: sudden drop in blood pressure upon standing.

Before initiating therapy, clinicians should consider several safety measures. - Monitor weight: track changes due to increased appetite. - Assess suicidal risk: evaluate mood and thoughts regularly, especially early in treatment. - Use caution in hepatic impairment: adjust dose if liver function is compromised. - Avoid abrupt discontinuation: taper gradually to reduce withdrawal symptoms. - Review concomitant CNS depressants: assess additive sedation risk. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Mirtazapine can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): heightened serotonin toxicity. - Central nervous system depressants (e.g., benzodiazepines, alcohol): excessive sedation.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole) or inducers (e.g., rifampicin): may alter plasma levels. - Antihypertensive drugs: potential additive blood‑pressure lowering effect. - Anticholinergic medications: may increase anticholinergic burden and dry mouth.